Rationale, Aims, and Objectives: While different imaging and treatment options are available in acute coronary syndrome (ACS) care, there is a lack of data regarding their use across Europe. We examined the diagnostic and treatment strategies in patients with known or suspected ACS as reported by physicians and identified variations in responses across European countries and geographical areas.
Conclusions: In this survey, respondents reported different diagnostic and treatment strategies in ACS care. These variations seem to have geographic components. Larger studies or real world data are needed to verify these observations and investigate their causes. More research is needed to compare the quality and efficiency of ACS care across countries and explore pathways for improvement. Evidence suggests differences in ACS care and outcomes within Europe. 1 However, variations in clinical practice and outcomes in ACS care have mainly been analyzed at a national level, providing information about the relative patterns and performance of different hospitals within individual countries. 2 Although this information is crucial to assess the performance of hospitals and identify inequalities in care at the national level, between-country comparisons have received little attention and would provide a complementary opportunity for learning from foreign health care systems and improving national performances. 2 Furthermore, given the lack of reliable data, establishing the status of the use of cardiovascular imaging in Europe has been a priority for influential European associations in the field. 3 While both surveys and registries are needed to verify whether clinical practice is in line with guidelines, 4 surveys offer the advantage to present specific clinical cases and obtain detailed information about diagnostic and management strategies.
In this context, we developed and used a web-based clinician survey to examine the diagnostic and treatment strategies reported by respondents and to identify potential variations in responses between countries or geographical areas within Europe. The focus was made on diagnostic tests (including coronary imaging and functional assessment) and revascularization treatment, in a range of clinical scenarios encompassing patients with known or suspected ACS.
| METHODS

| Study design
In order to assess clinical practice in ACS in Europe, we conducted an online clinician survey. The survey questions were formulated based on expert opinion and feedback collected from a European expert panel, which included five cardiologists and three radiologists.
A pilot phase was conducted before the survey was launched in March 2017. The survey was conducted using the online software "Google form" and was made available online. The target population for dissemination included non-invasive and interventional cardiologists, radiologists, and emergency physicians (including those completing their specialization).
No financial incentive was offered to participants and survey completion was voluntary. An ethics committee (EMC Rotterdam) reviewed the protocol and survey questions and concluded that this work was not subject to the Dutch law of medical research (WMO).
| Structure
A closed and structured format in English was chosen to enable clinicians to select their responses among multiple predefined choices.
First, an introduction provided the framework of the study and was followed by general questions regarding the respondents' work setting. Subsequently, respondents were asked about the diagnostic workup and the proportions of high-risk and low-to intermediate-risk patients suspected with ACS who would receive different imaging modalities in the respondent's practice setting. Section 5 contained questions about the treatments used for ST-elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI) patients while Section 6 focused on follow-up imaging.
Questions related to specific patient cases and clinical scenarios were disseminated throughout the survey and are summarized in Table 1 .
The survey questions can be found in Supporting Information. A pilottest phase was conducted after which the number of questions was reduced.
| Dissemination
The online survey link was circulated through email distribution lists and websites of national and European professional societies. The Mean percentages were calculated for two countries (Sweden and the United Kingdom) and three clusters of countries (Central Europe, Northern/Western Europe, and Southern Europe) that were created based on the geographic location of the respondents and expected commonalities in their health care system. Given the breakdown of participants per country, Sweden and the United Kingdom were extracted from the Northern/Western Europe cluster and isolated for more detailed analyses. Our statistical analyses rely on the assumption that respondents can be considered to be independent observations. Based on background information of the hospital (city, academic centre, and number of MI diagnosed), the maximum possible number of respondents coming from the same centre is very low, which means that the potential influence of this possibility on the results is low.
| Statistical analysis
The 95% confidence intervals (CIs) surrounding the mean estimates were computed using bootstrapping. 5 This involved randomly resampling the original samples with replacement 500 times, which corresponded to the number of replications needed to ensure stability and accuracy. Each bootstrapped sample yielded a bootstrap statistic (eg, mean frequency). The bootstrap distribution was computed from the 500 bootstrap statistics, per geographic area. Between-country and between-cluster comparisons of imaging and treatments were conducted using one-way ANOVA tests in SPSS (version 23). Statistical significance of the results was tested using a .05 level.
| General background regarding the availability and use of imaging modalities in the European Union
Previous studies reported considerable variation in the availability and use of imaging equipment in the European Union (EU). In 2015, Luxembourg recorded the highest number of angiography units per capita, followed by Italy and Sweden ( Table 2) . 6 
| RESULTS
We received responses from 74 clinicians. Of those, four non-European clinicians and one non-interpretable response set were excluded from the analysis. Among the 69 remaining respondents, 20 were from Sweden, 16 from the United Kingdom, 7 from Central Europe, 17 from Northern/Western Europe, and 9 from Southern Europe. Given that the survey was distributed by national professional societies, it was not possible to calculate the response rate. We acknowledge the fact that the response rate might be small. Details about the respondents' characteristics and work environment can be found in Table 3 .
| Initial diagnostic workup
On the basis of all answers, ECG combined with biochemical tests was reported as the mainstay of the first-line diagnostic workup for both patients were reported to receive it (see Figure S1 ).
| Diagnosis of a low risk patient
The Europe respondents strongly favoured stress tests in this context.
Significantly more UK respondents (56%) than Swedish respondents (10%) reported they would use coronary CTA (P = .002). Large variations were also observed regarding the use of echocardiogram:
while 71% of the respondents from Central Europe reported they would perform an echocardiogram, this was only 22% in Southern Europe and 25% in the United Kingdom. Interestingly, throughout the different geographic areas, a varying proportion of respondents (0%-22%) reported they would not perform any further examination.
| Imaging modality guiding treatment decision for patients with a high probability of ACS after biochemical tests
Overall, European respondents reported that an average of 60% of their patients presenting with a high probability of ACS after biochemical tests receive echocardiogram (see Figure S3 ). Furthermore, European respondents reported that an estimated 54% of their patients receive invasive coronary angiography without FFR compared to 37% receiving invasive coronary angiography with FFR. to be significantly greater in London than in other UK cities (P < .01).
| Average time between diagnosing a NSTEMI patient and performing invasive coronary angiography
The reported time between diagnosing an NSTEMI patient and performing invasive coronary angiography appear to vary substantially between and within the investigated areas. 
| Treatment of non-culprit lesions
In a second patient case, respondents were asked about how they would treat suspected non-culprit lesions in a 65-year-old NSTEMI patient presenting with a relatively good clinical status following the PCI of the culprit lesion. For this typical patient, slightly more than onequarter of the whole group of European respondents (19/69 = 28%) reported they would opt for conservative management with PCI only in the case of symptoms or reversible ischemia on stress tests (see Figure 4 ). Despite this trend, large variations are observed between responses across geographical areas: while this strategy was chosen by 56% and 57% of the respondents in Southern Europe and Central Europe, respectively, it was selected by only 16% to 25% of the respondents in the United Kingdom, Sweden, and Northern/Western Europe. Figure 4B ). No clinician from Southern Europe reported FFRguided PCI or immediate PCI in case of non-culprit lesions ( Figure 4B ). 
| DISCUSSION
To the best of our knowledge, this study presents the first online survey aimed at describing and analyzing reported diagnostic and treatment practices in ACS care across European regions and countries.
This study also provides detailed data related to a range of clinical scenarios that focus on strategies for specific patients.
Considerable variations in the respondents' answers were observed in both the diagnostic and treatment phases of patients with known or suspected ACS. In addition, comparative analyses revealed significant differences between the responses from Swedish and UK clinicians.
| Availability and reimbursement of diagnostic tests
The survey results showed that significantly lower frequencies of CTA use were reported by the Swedish respondents compared to the UK respondents. This may be explained by the facts that CTA is increasingly but not widely available in Sweden 9 and that CTA was incorporated into the UK NICE guidelines for patients at low risk of CAD. 10 By means of the specific patient cases presented in the survey, MRI was significantly more often reported by UK respondents than by Swedish respondents. Furthermore, respondents from London reported MRI to be more frequently used than respondents from other UK cities. These studies showed a rapid increase in use of cardiac MRI in patients with ACS and striking variations in use between high volume centres, in and around London, and the rest of the country. 11 A major factor that might explain the wide availability and the increased use of MRI scanners in the United Kingdom is the fact that 
| Treatments
The relatively high reported rates of PCI for reperfusion in STEMI patients and for revascularization in NSTEMI patients might reflect a widespread access to PCI throughout Europe. Despite this trend, lower rates of PCI were reported by UK respondents and variations in the answers were seen between all geographical areas; these two observations are consistent with previous studies. 19 European respondents reported PCI as the most common invasive treatment for STEMI and NSTEMI patients, although the efficacy and durability of CABG over PCI (for different groups of patients) was largely demonstrated. 20, 21 CABG remains highly recommended in patients characterized by multivessel disease, diabetes, or lesion complexity. In Sweden, the volume of CABG procedures has been declining over the past 35 years but considerable differences in the proportion of CABG and PCI out of the total of revascularization exist across hospitals. 9 This large variability might indicate that some patients do not receive the optimal treatment and highlight that further studies would be needed to investigate the optimal rates of CABG and PCI. Comprehensive research is needed on barriers to implementation, and more generally, on factors and structure that determine the diffusion, implementation, and variations in use of PCI within and between European countries.
Finally, we analyzed clinicians' responses regarding whether and when non-culprit lesions are treated and intended to identify possible geographic trends. While guidelines recommend a staged approach in the treatment of patients with STEMI and multi-vessel disease, 13 there is no evidence supporting the superiority of a staged over an immediate approach and no evidence regarding the best approach for NSTEMI patients. 22 By means of a survey, this study investigated clinical situations where evidence might remain uncertain or lacking. Indeed, the survey guaranteed that respondents answer to the exact same case, which allows preliminary international comparisons in clinical areas where registry data might not exist, capture limited details, be poor in quality, or not be available to third parties.
| LIMITATIONS
As a main limitation of our study, we acknowledge that a limited number of responses was received, implying a risk of selection bias and constraining generalizability of our results. Further research would be needed to ascertain and generalize our findings. However, our results are consistent with previous studies in the field and identify considerable differences in the reported strategies between areas.
| CONCLUSIONS
Our study revealed considerable variation in the reported modalities of diagnostic and treatment strategies in patients with suspected or established ACS across Europe. We have discussed potential causes for the reported differences in the utilization of these techniques that range from evidence regarding availability of techniques, guidelines, and reimbursement. Such differences may indicate that some patients do not receive the best available care and may have an important impact on the quality of health care and patient outcomes across geographical areas.
Complementary research might be possible to gather generalizable data and confirm these variations, investigate their causes and assess how much they reflect health care inefficiency and result in inequalities in patient outcomes. This could be done by either exploiting existing high quality registries or setting them up with a specific scope in terms of patient population. The latter might require considerable resources though. 
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